

Macular Degeneration Guideline Committee – development

Date: Monday 18th September 2017

Location: NICE offices, London - 11:00 to 15:00

Minutes: Final

Committee members present:	
Waqar Shah (Chair)	Present for all items
Katy Barnard (KB)	Present for all items
Alexander Foss (AF)	Present for all items
Carol McCletchie (CM)	Present for all items
Mary-Ann Sherratt (MS)	Present for all items
Cathy Yelf (CY)	Present for all items

In attendance:	
Jamie Elvidge (JE) NICE – Technical Analyst (HE)	Present for all items
Rupert Franklin (RF) NICE – Commissioning Manager	Present from item 5
Caroline Mulvihill Technical Advisor	Present until item 3
Vonda Murray (VM) NICE – Project Manager	Present for all items
Dave Nicholls (DN) NICE – Information Specialist	Present for all items
Gabriel Rogers (GR) NICE – Technical Advisor (HE)	Present for all items
Shreya Shukla (SH) Technical Analyst	Present until item item 2
Sue Spiers (SS) NICE – Associate Director	Present for all items

Apologies:	
Nick Beare (NB)	Committee member
Cathie Burke (CB)	Committee member
Andy Charley	Committee member (co-opted)
Louisa Crossley (LC)	NICE – Senior Medicines Advisor
Jennifer Evans (JE)	Committee member (co-opted)
Mary Freeman (MF)	Committee member
Ellen Rule (ER)	Committee member
Elizabeth Wick (EW)	Committee member

Item 1 Introductions, apologies, minutes, DOI and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 2nd post consultation meeting on age-related macular degeneration (AMD).

Apologies were noted, as recorded above.

The Chair invited each attendee to declare any new conflicts since the previous meeting.

WS updated a previous declaration from December 2016, he chaired an education session for GP's on Ophthalmology (unpaid). He updated his declaration to reflect that he has now received a payment.

Having reviewed all previous and new declarations of interest it was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

The minutes were reviewed from the Post consultation meeting; 6th September 2017. It was noted that Cathy Yelf had been omitted from the attendance list. Item 2 should read anti-oxidant, and not anti-toxin. The minutes were agreed to be an accurate record subject to the amendments noted above.

Post meeting note: Although unable to attend Nick Beare notified the NICE team that item 3 from the previous minutes should read “MB further addressed concerns raised by individual committee members about the changes referred to in paragraph 1 and the process by which they were made”.

The Chair provided an overview of the objectives for the day highlighting the information that would be discussed.

Item 2
Stakeholder consultation comments and committee discussion

GR led a discussion with the committee on the stakeholder comments in the following areas:

- Stopping anti-VEGF
- Geographic atrophy
- Role of optometrists
- Monitoring AMD

The committee agreed the responses to the stakeholder comments and any necessary changes to the guideline and / or recommendations.

LUNCH

Item 3
Stakeholder consultation comments and committee discussion

GR led a discussion with the committee on the stakeholder comments in the following areas:

- Information for patients
- Co-morbidities
- Learning disabilities

Macular Degeneration Guideline Committee post consultation minutes

The committee agreed the responses to the stakeholder comments and any necessary changes to the guideline and / or recommendations.

Item 4

Health economic model

GR and JE provided the committee with an update on the health economic model.

Item 4

Publication process

VM presented the next steps with regard to preparing the guideline for publication.

Item 5

Summary and next steps

The Chair briefly summarised the discussions from the meeting, and thanked the committee members for their hard work and input during the development process.